Month: December 2020

BALA CYNWYD, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020.The NBI is a modified market-cap weighted index designed to track the performance of a set of securities listed on the NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NBI is re-ranked each year and is calculated under a modified capitalization-weighted methodology. Additionally, the NBI forms the basis for a number of Exchange Traded Funds (ETFs), including the iShares...

BOCA RATON, Fla., Dec. 15, 2020 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that it has entered into a new exclusive distribution agreement with Ekpac Healthcare Ltd. to market Sensus SRT-100™ systems in China and Hong Kong.  This agreement is effective as of January 1, 2021. Sensus currently has 40 units installed throughout China in public and private hospitals as well as private clinics. It expects this relationship to accelerate SRT-100 unit population in the region.SRT-100 systems utilize Sensus’ proprietary low-energy x-ray technology known as superficial radiation therapy (SRT). China, which has more than 20% of the world’s population,...

IRVINE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) — Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, announced today that management is scheduled to present at the 13th Annual LD Micro Main Event Conference.Presentation details:Date: Tuesday, December 15, 2020Time: 12:40 – 1:00PM ESTInvestors can register for the conference HERE.   Following the conference, a webcast replay of the presentation will be available on the Investor section of the company’s website, www.oncocyte.com.About Oncocyte CorporationOncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical...

CHANDLER, Ariz., Dec. 15, 2020 (GLOBE NEWSWIRE) — To reduce the time, cost and risk of developing spaceflight-qualified systems, designers may start with Commercial-Off-The-Shelf (COTS) devices that can later be replaced by their space-qualified, radiation-tolerant equivalent parts available in plastic or ceramic packages featuring the same pinout distribution.  Microchip Technology Inc. (Nasdaq: MCHP) today announced a radiation-tolerant, 64 Megabit (Mbit) parallel-interface SuperFlash memory device with unrivaled Total Ionizing Dose (TID) tolerance for maximum reliability and robustness in the harsh radiation environment of space missions. It is an ideal companion to Microchip’s space-ready microcontrollers (MCUs), microprocessors (MPUs) and Field Programmable Gate Arrays (FPGAs) that provide the building blocks for this scalable...

EXTON, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement (the “Purchase Agreement”), resulting in aggregate proceeds of up to $20.7 million in common stock and warrant investment by funds affiliated with an institutional investor. Pursuant to the Purchase Agreement, under the second tranche Idera sold 2,747,252 shares of common stock (or common stock equivalents), together with accompanying warrants to purchase 1,373,626 shares of common stock, for aggregate gross proceeds of $5.0 million. The placement is exempt from the registration requirements of the Securities Act of 1933, as amended.  “We believe this funding and other financial arrangements we have in place reflect optimism in the significant...

PLANO, Texas, Dec. 15, 2020 (GLOBE NEWSWIRE) — DZS (Nasdaq: DZSI), a global leader of mobile, fixed broadband and enterprise access networking solutions representing 1,000+ communications service providers and enterprise customers, today announced the appointment of two accomplished leaders charged with expanding the adoption of the company’s latest innovations and cultivating a customer-first culture. Jay Hilbert has been named Executive Vice President of Americas, Europe, Middle East/Africa (AEMEA) Sales and Bill Ko has been appointed Executive Vice President of Asia Sales.A trusted access networking innovator and technology partner to many of the world’s most admired communications service providers and enterprises spanning 100+ countries, DZS continues its relentless pursuit of a customer-first culture. The growing demand for...

BEVERLY, Mass., Dec. 15, 2020 (GLOBE NEWSWIRE) — LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce it has received a purchase order for a MiQLab™ system from Ethos Discovery.Dr. Chand Khanna, DVM, PhD, DACVIM (Onc), DACVP (Hon), the President of Ethos Discovery, comments, “We are very excited to purchase a MiQLab system and look forward to using the validated test panel to quickly diagnose infections. In veterinary health, there are many unmet clinical diagnostic needs where LexaGene’s technology can be of great value.” He continues, “In 2021, we will collaborate with LexaGene on expanding the MiQLab’s capabilities to pursue additional diagnostic innovation in areas that are important for Ethos....

FORT LAUDERDALE, Fla., Dec. 15, 2020 (GLOBE NEWSWIRE) — via InvestorWire – The Movie Studio, Inc. (OTC: MVES) (the Company”) is pleased to announce that it has successfully secured a 6,400-square-foot Studio facility in the prestigious Ft. Lauderdale Galleria Mall. The location will house the Company’s vertically integrated business model and, when completed, will include Corporate Management Administration and Systems Administration offices, Content Creation, and Edit and Voiceover Suites. The facility will also house Social Media, Location and Product Placement, Production, Talent and Wardrobe Departments and OTT platform suites. The Production Area will encompass a 15×20 stage with projection backdrops, professional green screen, greenroom and set production and equipment storage areas.The Company intends to monetize...

FREDERICK, MD, Dec. 15, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — BioElectronics Corporation (OTC PINK: BIEL), (www.bielcorp.com) is pleased to announce that it has executed an OEM agreement with KT Health, LLC to bring its innovative pain management devices to encompass retail and e-commerce distribution throughout North America, as well as several additional key international markets.The agreement incorporates BioElectronics’ ActiPatch® technology into KT Health’s KT Recovery+® product line, which will be marketed under the proprietary trade name KT Recovery+ Wave™. KT Health will leverage BioElectronics’ FDA 510(k) clearance to market, promote, and distribute the devices for the treatment of general musculoskeletal pain. As part of this agreement BioElectronics will cease active promotion of the brand name ActiPatch in...